Natural products as leads to anticancer drugs.

M Gordaliza
Author Information
  1. M Gordaliza: Departamento de Química Farmacéutica, Facultad de Farmacia, Universidad de Salamanca, Salamanca, Spain. mliza@usal.es

Abstract

Throughout history, natural products have afforded a rich source of compounds that have found many applications in the fields of medicine, pharmacy and biology. Within the sphere of cancer, a number of important new commercialised drugs have been obtained from natural sources, by structural modification of natural compounds, or by the synthesis of new compounds, designed following a natural compound as model. The search for improved cytotoxic agents continues to be an important line in the discovery of modern anticancer drugs. The huge structural diversity of natural compounds and their bioactivity potential have meant that several products isolated from plants, marine flora and microorganisms can serve as "lead" compounds for improvement of their therapeutic potential by molecular modification. Additionally, semisynthesis processes of new compounds, obtained by molecular modification of the functional groups of lead compounds, are able to generate structural analogues with greater pharmacological activity and with fewer side effects. These processes, complemented with high-throughput screening protocols, combinatorial chemistry, computational chemistry and bioinformatics are able to afford compounds that are far more efficient than those currently used in clinical practice. Combinatorial biosynthesis is also applied for the modification of natural microbial products. Likewise, advances in genomics and the advent of biotechnology have improved both the discovery and production of new natural compounds.

References

  1. Methods Find Exp Clin Pharmacol. 2007 May;29(4):303-11 [PMID: 17609744]
  2. J Clin Oncol. 1999 Jun;17 (6):1751-9 [PMID: 10561212]
  3. Free Radic Biol Med. 2007 Sep 15;43(6):968-75 [PMID: 17697941]
  4. IUBMB Life. 2002 Apr-May;53(4-5):269-74 [PMID: 12121008]
  5. J Med Chem. 2007 Oct 18;50(21):5183-92 [PMID: 17894480]
  6. Phytochemistry. 2007 Jul;68(14):1844-54 [PMID: 17184797]
  7. J Nat Prod. 2003 Jul;66(7):1022-37 [PMID: 12880330]
  8. Mol Cancer Ther. 2005 Feb;4(2):333-42 [PMID: 15713904]
  9. Pharm Unserer Zeit. 2005;34(2):98-103 [PMID: 15803792]
  10. J Nat Prod. 2004 Feb;67(2):273-83 [PMID: 14987069]
  11. Anticancer Drugs. 1997 Oct;8(9):811-22 [PMID: 9402307]
  12. Bioorg Med Chem Lett. 2006 Feb 15;16(4):974-7 [PMID: 16298526]
  13. Clin Pharmacokinet. 1996 Aug;31(2):85-102 [PMID: 8853931]
  14. J Biol Chem. 1985 Nov 25;260(27):14873-8 [PMID: 2997227]
  15. Adv Exp Med Biol. 2007;595:77-103 [PMID: 17569206]
  16. Med Res Rev. 1999 Nov;19(6):569-96 [PMID: 10557371]
  17. Curr Probl Dermatol. 1996;24:227-32 [PMID: 8743274]
  18. Clin Transl Oncol. 2006 Oct;8(10):717-28 [PMID: 17074670]
  19. Nat Prod Rep. 2006 Feb;23(1):26-78 [PMID: 16453031]
  20. Expert Opin Investig Drugs. 2003 Aug;12(8):1367-83 [PMID: 12882622]
  21. Nat Rev Drug Discov. 2005 Mar;4(3):206-20 [PMID: 15729362]
  22. N Engl J Med. 2004 Jun 3;350(23 ):2335-42 [PMID: 15175435]
  23. Bioorg Med Chem Lett. 2007 Sep 15;17(18):5204-9 [PMID: 17643301]
  24. Cancer Lett. 2007 Jan 8;245(1-2):144-8 [PMID: 16466851]
  25. Nature. 2004 Dec 16;432(7019):829-37 [PMID: 15602548]
  26. Prog Drug Res. 1989;33:169-266 [PMID: 2687938]
  27. J Nat Prod. 2006 Oct;69(10 ):1384-8 [PMID: 17067147]
  28. Science. 2005 Oct 21;310(5747):451-3 [PMID: 16239465]
  29. Curr Med Chem. 2004 Sep;11(18):2443-66 [PMID: 15379707]
  30. Curr Pharm Des. 2000 Dec;6(18):1811-39 [PMID: 11102564]
  31. Phytochemistry. 2000 May;54(2):115-20 [PMID: 10872202]
  32. J Med Chem. 1999 Jul 1;42(13):2441-6 [PMID: 10395485]
  33. Lung Cancer. 2007 Jul;57(1):84-8 [PMID: 17399850]
  34. Bioorg Med Chem. 1995 Sep;3(9):1203-10 [PMID: 8564411]
  35. Farmaco. 2001 Apr;56(4):297-304 [PMID: 11421258]
  36. Nat Prod Rep. 2005 Apr;22(2):162-95 [PMID: 15806196]
  37. Clin Rheumatol. 1987 Mar;6(1):27-38 [PMID: 3581696]
  38. Nat Rev Cancer. 2004 Apr;4(4):253-65 [PMID: 15057285]
  39. Cancer Chemother Rep. 1968 Jun;52(4):455-61 [PMID: 5743691]
  40. Bioorg Med Chem Lett. 2000 Feb 21;10(4):315-7 [PMID: 10714489]
  41. Curr Med Chem. 2001 Oct;8(12):1467-86 [PMID: 11562277]
  42. Biochimie. 1998 Mar;80(3):207-22 [PMID: 9615861]
  43. Lancet Oncol. 2007 Jan;8(1):13 [PMID: 17348119]
  44. N Engl J Med. 2004 Jul 22;351(4):391-2 [PMID: 15269321]
  45. Chem Soc Rev. 2007 Aug;36(8):1207-26 [PMID: 17619682]
  46. Nat Prod Rep. 2007 Feb;24(1):31-86 [PMID: 17268607]
  47. Toxicon. 2004 Sep 15;44(4):441-59 [PMID: 15302526]
  48. Semin Oncol. 1997 Feb;24(1 Suppl 5):S5-12-S5-18 [PMID: 9122737]
  49. Curr Opin Biotechnol. 1997 Dec;8(6):708-12 [PMID: 9425661]
  50. Gynecol Oncol. 2007 Mar;104(3):591-5 [PMID: 17045635]
  51. Pharmacol Ther. 1991;51(2):257-67 [PMID: 1784631]
  52. Bioorg Med Chem. 2006 May 1;14(9):3062-8 [PMID: 16406792]
  53. Bioorg Med Chem. 2005 Nov 15;13(22):6218-25 [PMID: 16061385]
  54. Angew Chem Int Ed Engl. 2003 Sep 5;42(34):3996-4028 [PMID: 12973759]
  55. Curr Pharm Des. 2005;11(13):1695-717 [PMID: 15892669]
  56. Mini Rev Med Chem. 2005 Mar;5(3):307-11 [PMID: 15777264]
  57. Curr Opin Drug Discov Devel. 2005 Mar;8(2):207-27 [PMID: 15782545]
  58. Chem Pharm Bull (Tokyo). 1991 Jun;39(6):1446-50 [PMID: 1934165]
  59. Clin Pharm. 1989 Apr;8(4):274-93 [PMID: 2653712]
  60. Med Res Rev. 1998 Sep;18(5):299-314 [PMID: 9735871]
  61. Ann Pharmacother. 1998 Dec;32(12 ):1324-33 [PMID: 9876815]
  62. Cancer Res. 1996 Jun 15;56(12):2809-14 [PMID: 8665518]
  63. Ann Oncol. 1997 Sep;8(9):837-55 [PMID: 9358934]
  64. Bioorg Med Chem. 2005 Nov 1;13(21):5892-908 [PMID: 16129603]
  65. Chem Pharm Bull (Tokyo). 2003 Mar;51(3):255-61 [PMID: 12612407]
  66. Free Radic Biol Med. 2007 Nov 1;43(9):1313-21 [PMID: 17893044]
  67. Clin Cancer Res. 2002 Mar;8(3):641-61 [PMID: 11895891]
  68. J Med Chem. 2004 Feb 26;47(5):1214-22 [PMID: 14971901]
  69. J Med Chem. 2002 Dec 19;45(26):5620-3 [PMID: 12477344]
  70. J Org Chem. 2006 Oct 27;71(22):8329-51 [PMID: 17064003]
  71. J Nat Prod. 2002 Jul;65(7):1065-8 [PMID: 12141878]
  72. Curr Med Chem. 2001 Sep;8(11):1363-81 [PMID: 11562272]
  73. Expert Rev Anticancer Ther. 2006 Oct;6(10):1433-47 [PMID: 17069528]
  74. Bioorg Med Chem Lett. 1998 Jun 2;8(11):1391-6 [PMID: 9871772]
  75. Drug Saf. 2006;29(3):209-30 [PMID: 16524321]
  76. J Med Chem. 1991 Jan;34(1):98-107 [PMID: 1846923]
  77. Cancer Treat Rev. 2006 Apr;32(2):106-18 [PMID: 16473470]
  78. Chem Pharm Bull (Tokyo). 2001 Jun;49(6):773-5 [PMID: 11411537]
  79. Bioorg Med Chem Lett. 2007 Oct 15;17 (20):5624-9 [PMID: 17768050]
  80. N Engl J Med. 2000 Sep 28;343 (13):905-14 [PMID: 11006366]
  81. Trends Mol Med. 2007 Aug;13(8):353-61 [PMID: 17644431]
  82. Nat Prod Rep. 2007 Apr;24(2):327-57 [PMID: 17390000]
  83. Nat Prod Rep. 2006 Jun;23(3):347-56 [PMID: 16741583]
  84. J Nat Prod. 2007 Mar;70(3):461-77 [PMID: 17309302]
  85. Expert Opin Pharmacother. 2005 Jun;6(7):1073-94 [PMID: 15957963]
  86. Eur J Med Chem. 2000 Jul-Aug;35(7-8):691-8 [PMID: 10960184]
  87. Nat Prod Rep. 2007 Feb;24(1):87-108 [PMID: 17268608]
  88. Cancer Treat Rev. 2006 May;32(3):166-79 [PMID: 16527420]
  89. J Nat Prod. 2004 Aug;67(8):1216-38 [PMID: 15332835]
  90. Ann Oncol. 1994;5 Suppl 2:91-5 [PMID: 7515652]
  91. J Ethnopharmacol. 2005 Aug 22;100(1-2):72-9 [PMID: 16009521]
  92. Pharm Res. 2001 Jun;18(6):846-51 [PMID: 11474790]
  93. Antivir Chem Chemother. 1998 May;9(3):263-7 [PMID: 9875405]
  94. Biochem Pharmacol. 2007 Sep 1;74(5):659-71 [PMID: 17498667]
  95. Nature. 1994 Feb 17;367(6464):630-4 [PMID: 7906395]
  96. Ann Oncol. 2003 May;14 (5):805-6 [PMID: 12702539]
  97. Org Lett. 2002 Sep 19;4(19):3187-9 [PMID: 12227745]
  98. Cancer Res. 1994 Mar 15;54(6):1431-9 [PMID: 8137244]
  99. Curr Med Chem. 1998 Jun;5(3):205-52 [PMID: 9562603]
  100. Curr Probl Cancer. 2007 Jul-Aug;31(4):243-305 [PMID: 17645940]
  101. Cell Cycle. 2005 Feb;4(2):279-89 [PMID: 15611640]
  102. Curr Opin Drug Discov Devel. 2007 Mar;10(2):130-44 [PMID: 17436548]
  103. Oncologist. 2002;7 Suppl 5:3-10 [PMID: 12324628]
  104. Arch Pharm (Weinheim). 1994 Mar;327(3):175-9 [PMID: 8179476]
  105. Bioorg Med Chem Lett. 2007 Mar 1;17(5):1381-5 [PMID: 17188868]
  106. Chem Biodivers. 2005 Dec;2(12 ):1597-623 [PMID: 17191958]
  107. Clin Cancer Res. 1999 Jan;5(1):3-5 [PMID: 9918195]
  108. Int J Pharm. 2007 Oct 1;343(1-2):270-6 [PMID: 17706383]
  109. Immunopharmacol Immunotoxicol. 2001 Feb;23(1):83-95 [PMID: 11322652]
  110. J Nat Prod. 2004 Dec;67(12):2141-53 [PMID: 15620274]
  111. Cancer Lett. 2007 Oct 8;255(2):170-81 [PMID: 17448598]
  112. J Clin Pharmacol. 2007 May;47(5):579-88 [PMID: 17442684]
  113. Nature. 2006 Oct 26;443(7114):904-5 [PMID: 17066005]
  114. Appl Microbiol Biotechnol. 2001 Mar;55(2):135-42 [PMID: 11330705]
  115. Mini Rev Med Chem. 2005 Jan;5(1):1-12 [PMID: 15638787]

MeSH Term

Animals
Antineoplastic Agents
Biological Products
Drug Evaluation, Preclinical
Humans
Neoplasms

Chemicals

Antineoplastic Agents
Biological Products

Word Cloud

Created with Highcharts 10.0.0compoundsnaturalproductsnewmodificationdrugsstructuralimportantobtainedimproveddiscoveryanticancerpotentialmolecularprocessesablechemistryThroughouthistoryaffordedrichsourcefoundmanyapplicationsfieldsmedicinepharmacybiologyWithinspherecancernumbercommercialisedsourcessynthesisdesignedfollowingcompoundmodelsearchcytotoxicagentscontinueslinemodernhugediversitybioactivitymeantseveralisolatedplantsmarinefloramicroorganismscanserve"lead"improvementtherapeuticAdditionallysemisynthesisfunctionalgroupsleadgenerateanaloguesgreaterpharmacologicalactivityfewersideeffectscomplementedhigh-throughputscreeningprotocolscombinatorialcomputationalbioinformaticsaffordfarefficientcurrentlyusedclinicalpracticeCombinatorialbiosynthesisalsoappliedmicrobialLikewiseadvancesgenomicsadventbiotechnologyproductionNaturalleads

Similar Articles

Cited By